Eczema affects up to 10% of adults and 25% of children in the U.S., causing itchy, inflamed skin that can disrupt sleep and daily life. Treatment has relied on topical steroids and immune suppressants, but several new drug classes approved since 2017 now target specific immune pathways. Many people still struggle to find treatments that work without significant side effects.
What's actually going on in research
Trials are testing JAK inhibitors in pill and cream form, monoclonal antibodies that block specific immune signals, and drugs targeting itch pathways directly. Researchers are also studying the skin barrier defect in eczema, testing whether restoring barrier function can prevent flares, and investigating the role of staph bacteria that colonize eczema skin.
JAK inhibitors
Pills like upadacitinib and abrocitinib block JAK enzymes that drive eczema inflammation. Topical JAK inhibitors now offer another option for people who want to avoid systemic treatment.
Targeted biologics
Dupilumab blocks IL-4 and IL-13, two proteins that drive eczema inflammation, and was FDA-approved in 2017. Newer biologics targeting IL-13 alone or other immune pathways are being tested to see if they work as well with fewer injections.
Microbiome approaches
Studies are testing whether killing staph bacteria on the skin or adding helpful bacteria can reduce flares. Some trials are testing live biotherapeutic products applied directly to eczema skin.
What to know before you search
Eligibility typically depends on eczema severity, body surface area affected, response to prior topical treatments, and sometimes whether you have specific biomarkers or high levels of certain immune proteins.
What types of trials are currently open
- Treatment trials — Testing new pills, injections, or creams against placebo or standard treatment to see if they reduce itch and skin inflammation.
- Maintenance trials — Testing whether new treatments can prevent flares over months or years in people whose eczema is under control.
- Pediatric trials — Testing drugs in children with eczema, often after they've been studied in adults.
- Barrier repair trials — Testing creams or treatments that aim to fix the skin barrier defect in eczema rather than just suppressing inflammation.
- Microbiome trials — Testing treatments that change the bacteria living on eczema skin, including targeted antimicrobials and live bacterial products.
Recently added Eczema trials
Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis
Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention. The investigators aim to identify an accessible, effective digital health intervention for these patients. The investigators hypothesize that regular use of a digital mindfulness meditation app will improve disease control and quality of life in adolescents with moderate to severe atopic dermatitis based on validated survey measures.
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.
Find Eczema trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.